Non-motor symptoms of Parkinson's disease

International Journal of Gerontology

Volumn 1, Issue 2, 2007, Pages 53-64

  Hou, Jyh Gong Gabriel ^a   Lai, Eugene C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Dementia; Depression; Dysautonomia; Non motor symptoms; Parkinson's disease; Psychosis; Sleep

Indexed keywords

BENZODIAZEPINE; BOTULINUM TOXIN; BUSPIRONE; CLONAZEPAM; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUDROCORTISONE; GABAPENTIN; LEVODOPA; MEMANTINE; MIDODRINE; MODAFINIL; OLANZAPINE; OPIATE; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; ROPINIROLE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGITATION; ANXIETY DISORDER; AUTONOMIC DYSFUNCTION; BRAIN DEPTH STIMULATION; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DEMENTIA; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISORIENTATION; DRUG DOSE REDUCTION; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; EVENING DOSAGE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HIGH FIBER DIET; HUMAN; HYPERHIDROSIS; INTESTINE MOTILITY; MANIA; MENTAL DISEASE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; REVIEW; SEDATION; SEROTONIN SYNDROME; SIDE EFFECT; SLEEP DISORDER; XEROSTOMIA;

EID: 39549095999     PISSN: 18739598     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1873-9598(08)70024-3     Document Type: Review

References (127)

1. Parkinson J. An essay on the shaking palsy. J Neuropsychiatry Clin Neurosci 2002; 14: 223-36; Discussion, 222.
2. Tanner CM, Aston DA. Epidemiology of Parkinson's disease and akinetic syndromes. Curr Opin Neurol 2000; 13: 427-30.
3. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235-45.
4. Adler CH. Nonmotor complications in Parkinson's disease. Mov Disord 2005; 20 (Suppl 11): S23-9.
5. Habermann-Little B. An analysis of the prevalence and etiology of depression in Parkinson's disease. J Neurosci Nurs 1991; 23: 165-9.
6. Kostic VS, Filipovic SR, Lecic D, Momcilovic D, Sokic D, Sternic N. Effect of age at onset on frequency of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 1265-7.
7. Hantz P, Caradoc-Davies G, Caradoc-Davies T, Weatherall M, Dixon G. Depression in Parkinson's disease. Am J Psychiatry 1994; 151: 1010-4.
8. Pollock M, Hornabrook RW. The prevalence, natural history and dementia of Parkinson's disease. Brain 1966; 89: 429-48.
9. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2: 229-37.
10. Rippon GA, Marder KS. Dementia in Parkinson's disease. Adv Neurol 2005; 96: 95-113.
11. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996; 46: 388-93.
12. Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000; 123: 331-9.
13. Magerkurth C, Schnitzer R, Braune S. Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life. Clin Auton Res 2005; 15: 76-82.
14. Hobson P, Islam W, Roberts S, Adhiyman V, Meara J. The risk of bladder and autonomic dysfunction in a community cohort of Parkinson's disease patients and normal controls. Parkinsonism Relat Disord 2003; 10: 67-71.
15. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov Disord 2004; 19: 1306-12.
16. Siddiqui MF, Rast S, Lynn MJ, Auchus AP, Pfeiffer RF. Autonomic dysfunction in Parkinson's disease: a comprehensive symptom survey. Parkinsonism Relat Disord 2002; 8: 277-84.
17. 123l] MIBG separates Parkinson's disease from multiple system atrophy. Neurology 1999; 53: 1020-5.
18. Taki J, Nakajima K, Hwang E-H, Matsunari I, Komai K, Yoshita M, et al. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 2000; 27: 566-73.
19. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991; 50: 743-55.
20. Brown AS, Gershon S. Dopamine and depression. J Neural Transm Gen Sect 1993; 91: 75-109.
21. Middleton FA, Strick PL. Basal ganglia output and cognition: evidence from anatomical, behavioral, and clinical studies. Brain Cogn 2000; 42: 183-200.
22. Clower DM, Dum RP, Strick PL. Basal ganglia and cerebellar inputs to 'AIP'. Cereb Cortex 2005; 15: 913-20.
23. Benarroch EE. Central neurotransmitters and neuromodulators in cardiovascular regulation. In: Mathias CJ, Bannister R, eds. Autonomic Failure, 4th edition. Oxford: Oxford University Press, 1999; 37-44.
24. Goldstein DS, Holmes CS, Dendi R, Bruce SR, Li ST. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 2002; 58: 1247-55.
25. Dewey RB Jr. Autonomic dysfunction in Parkinson's disease. Neurol Clin 2004; 22 (3 Suppl): S127-39.
26. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002; 249 (Suppl 3): III/1-5.
27. Braak H, Del Tredici K, Rub U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-210.
28. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-34.
29. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. Brain serotonin 5HT1A receptors in Parkinson's disease with and without depression measured by positron emission tomography with 11C-WAY 10635. Mov Disord 2000; 15: 213.
30. Mossner R, Henneberg A, Schmitt A, Syagailo YV, Grassle M, Hennig T, et al. Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol Psychiatry 2001; 6: 350-2.
31. Veazey C, Aki SO, Cook KF, Lai EC, Kunik ME. Prevalence and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2005; 17: 310-23.
32. Henderson R, Kurlan R, Kersun JM, Como P. Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992; 4: 257-64.
33. Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001; 13: 187-96.
34. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992; 149: 443-54.
35. Cole SA, Woodard JL, Juncos JL, Kogos JL, Youngstrom EA, Watts RL. Depression and disability in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1996; 8: 20-5.
36. Starkstein SE, Petracca G, Chemerinski E, Teson A, Sabe L, Merelllo M, et al. Depression in classic versus akinetic-rigid Parkinson's disease. Mov Disord 1998; 13: 29-33.
37. Schrag A, Jahanshahi M, Quinn NP. What contributes to depression in Parkinson's disease? Psychol Med 2001; 31: 65-73.
38. Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology 1997; 48: 1070-7.
39. Weintraub D, Morales KH, Moberg PJ, Bilker WB, Balderston C, Duda JE, et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005; 20: 1161-9.
40. Aarsland D, Larsen JP, Waage O, Langeveld JH. Maintenance of electroconvulsive therapy for Parkinson's disease. Convuls Ther 1997; 13: 274-7.
41. Moellentine C, Rummans T, Ahlskog JE, Harmsen WS, Suman VJ, O'Connor MK, et al. Effectiveness of ECT in patients with parkinsonism. J Neuropsychiatry Clin Neurosci 1998; 10: 187-93.
42. Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry 1993; 34: 465-70.
43. Walsh K, Bennett G. Parkinson's disease and anxiety. Postgrad Med J 2001; 77: 89-93.
44. Menza MA, Sage J, Marshall E, Cody R, Duvoisin R. Mood changes and "on-off" phenomena in Parkinson's disease. Mov Disord 1990; 5: 148-51.
45. Menza M, Marlin H, Kaufman K, Mark M, Lauritano M. Citalopram treatment of depression in Parkinson's disease. the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci 2004; 16: 315-9.
46. Weintraub D, Stern MB. Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatry 2005; 13: 844-51.
47. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387-92.
48. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9: 357-81.
49. Calabresi P, Picconi B, Parnetti L, Di Filippo M. A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol 2006; 5: 974-83.
50. Cooper B, Holmes C. Previous psychiatric history as a risk factor for late-life dementia: a population-based case-control study. Age Ageing 1998; 27: 181-8.
51. Haugarvoll K, Aarsland D, Wentzel-Larsen T, Larsen JP. The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease. Acta Neurol Scand 2005- 112: 386-90.
52. Pillon B, Boller F, Levy R, Dubois B. Cognitive deficits and dementia in Parkinson's disease. In: Boller F, Cappa S, eds. Aging and Dementia. Amsterdam: Elsevier, 2001; 311-72.
53. Bertrand E, Lechowicz W, Szpak GM, Lewandowska E, Dymecki J, Wierzba-Bobrowicz T. Limbic neuropathology in idiopathic Parkinson's disease with concomitant dementia. Folia Neuropathol 2004; 42: 141-50.
54. Iseki E. Dementia with Lewy bodies: reclassification of pathological subtypes and boundary with Parkinson's disease or Alzheimer's disease. Neuropathology 2004; 24: 72-8.
55. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-72.
56. McKeith IG, Ballard CG, Perry RH, Ince PG, O'Brien JT, Neill D, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000; 54: 1050-8.
57. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-18.
58. Siddiqui MA, Wagstaff Aj. Rivastigmine: in Parkinson's disease dementia. CNS Drugs 2006; 20: 739-47.
59. Boeve BF. Evidence for cholinesterase-inhibitor therapy for dementia associated with Parkinson's disease. Lancet Neurol 2005; 4: 137-8.
60. Inzelberg R, Bonuccelli U, Schechtman E, Miniowich A, Strugatsky R, Ceravolo R, et al. Association between amantacline and the onset of dementia in Parkinson's disease. Mov Disord 2006; 21: 1375-9.
61. Menendez-Gonzalez M, Calatayud MT, Blazquez-Menes B. Exacerbation of Lewy bodies dementia due to memantine. J Alzheimers Dis 2005; 8: 289-91.
62. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord 2005; 20: 130-40.
63. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995; 45: 669-71.
64. Chou KL, Messing S, Oakes D, Feldman PD, Breier A, Friedman JH. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 2005; 28: 215-9.
65. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000; 123: 733-45.
66. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999; 14: 866-74.
67. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review); report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 996-1002.
68. Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 2006; 29: 331-7.
69. Tariot PN, Schneider L, Katz IR, Mintzer JE, Street J, Copenhaver M, et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry 2006; 14: 767-76.
70. Yang SY, Kao Yang YH, Chong MY, Yang YH, Chang WH, Lai CS. risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clin Pharmacol Ther 2007; 81: 586-94.
71. Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S. Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis. Eur Neuropsychopharmacol 2007; 17: 165-71.
72. Stacy M. Sleep disorders in Parkinson's disease: epidemiology and management. Drugs Aging 2002; 19: 733-9.
73. Onofrj M, Thomas A, D'Andreamatteo G, Iacono D, Luciano AL, Di Rollo A, et al. Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up. Neurol Sci 2002; 23 (Suppl 2): S91-4.
74. Lauterbach EC. The neuropsychiatry of Parkinson's disease and related disorders. Psychiatr Clin North Am 2004; 27: 801-25.
75. Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006; 66: 845-51.
76. De CockVC, Vidailhet M, Leu S, Texeira A, Apartis E, Elbaz A, et al. Restoration of normal motor control in Parkinson's disease during REM sleep. Brain 2007; 130: 450-6.
77. Barone P, Amboni M, Vitale C, Bonavita V. Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson's disease. Neurology 2004; 63 (8 Suppl 3): S35-8.
78. Poryazova RG, Zachariev ZI. REM sleep behavior disorder in patients with Parkinson's disease. Folia Med (Plovdiv) 2005; 47: 5-10.
79. Rye DB. Excessive daytime sleepiness and unintended sleep in Parkinson's disease. Curr Neurol Neurosci Rep 2006; 6: 169-76.
80. Andreu N, Chale JJ, Senard JM, Thalamas C, Montastruc JL, Rascol O. L-dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin Neuropharmacol 1999; 22: 15-23.
81. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in Persons taking pramipexole and ropinirole. Neurology 1999; 52: 1908-10.
82. Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology 2006; 67: 853-8.
83. Hogl B, Saletu M, Brandauer E, Glatzl S, Frauscher B, Seppi K, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002; 25: 905-9.
84. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003; 18: 287-93.
85. Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005; 76: 1636-9.
86. Garcia-Borreguero D, Odin P, Serrano C. Restless legs syndrome and PD: a review of the evidence for a possible association. Neurology 2003; 61 (6 Suppl 3): S49-55.
87. Rye DB. Parkinson's disease and RLS: the dopaminergic bridge. Sleep Med 2004; 5: 317-28.
88. Poewe W, Hogl B. Akathisia, restless legs and periodic limb movements in sleep in Parkinson's disease. Neurology 2004; 63 (8 Suppl 3): S12-6.
89. Krishnan PR, Bhatia M, Behari M. Restless legs syndrome in Parkinson's disease: a case-controlled study. Mov Disord 2003; 18: 181-5.
90. Poewe W, Hogl B. Akathisia, restless legs and periodic limb movements in sleep in Parkinson's disease. Neurology 2004; 63 (8 Suppi 3): S12-6.
91. Nomura T, Inoue Y, Nakashima K. Clinical characteristics of Restless legs syndrome in patients with Parkinson's disease. J Neurol Sci 2006; 250: 39-44.
92. Ondo W, Romanyshyn J, Vuong KD, Lai D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 2004; 61: 1393-7.
93. Montplaisir J, Karrasch J, Haan J, Volc D. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord 2006; 21: 1627-35.
94. Bogan RK, Fry JM, Schmidt MH, Carson SW, Ritchie SY; TREAT RLS US Study Group. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006; 81: 17-27.
95. Oertel WH, Stiasny-Kolster K, Bergtholdt B, Hallstrom Y, Albo J, Leissner L, et al. Pramipexole RLS Study Group. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord 2007; 22: 213-9.
96. Lesage S, Hening WA. The restless legs syndrome and periodic limb movement disorder: a review of management. Semin Neurol 2004; 24: 249-59.
97. Kurlan R, Richard IH, Deeley C, Medication tolerance and augmentation in restless legs syndrome: the need for drug class rotation. J Gen Intern Med 2006; 21: C1-4.
98. Montagna P. The treatment of restless legs syndrome. Neurol Sci 2007; 28 (Suppl 1): S61-6.
99. Driver-Dunckley E, Evidente VG, Adler CH, Hillman R, Hernandez J, Fletcher G, et al. Restless legs syndrome in Parkinson's disease patients may improve with subthalamic stimulation. Mov Disord 2006; 21: 1287-9.
100. Benarroch EE. Central neurotransmitters and neuromodulators in cardiovascular regulation. In: Mathias CJ, Bannister R, eds. Autonomic Failure, 4th edition. Oxford: Oxford University Press, 1999; 37-44.
101. Goldstein DS. Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res 2006; 16: 46-54.
102. Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol 2000; 57: 1461-3.
103. Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Saf 2003; 26: 439-44.
104. Desboeuf K, Grau M, Riche F, Fradin M, Bez J, Montastruc JL, et al. Prevalence and costs of parkinsonian syndromes associated with orthostatic hypotension. Therapie 2006; 61: 93-9.
105. Khan NL, Graham E, Critchley P, Schrag AE, Wood NW, Lees AJ, et al. Parkin disease: a phenotypic study of a large case series. Brain 2003; 126: 1279-92.
106. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003; 2: 107-16.
107. Kaye J, Gage H, Kimber A, Storey L, Trend P. Excess burden of constipation in Parkinson's disease: a pilot study. Mov Disord 2006; 21: 1270-3.
108. Byrne KG, Pfeiffer R, Quigley EM. Gastrointestinal dysfunction in Parkinson's disease: a report of clinical experience at a single center. J Clin Gastroenterol 1994; 19: 11-6.
109. Ueki A, Otsuka M. Life style risks of Parkinson's disease: association between decreased water intake and constipation. J Neurol 2004; 251 (Suppl 7): vii18-23.
110. Jost WH, Eckardt VF. Constipation in idiopathic Parkinson's disease. Scand J Gastroenterol 2003; 38: 681-6.
111. Miller N, Noble E, Jones D, Burn D. Hard to swallow: dysphagia in Parkinson's disease. Age Ageing 2006; 35: 614-8.
112. Diamond A, Jankovic J. Treatment of advanced Parkinson's disease. Expert Rev Neurother 2006; 6: 1181-97.
113. Sempere AP, Duarte J, Cabezas C, Claveria LE, Coria F. Aggravation of parkinsonian tremor by cisapride. Clin Neuropharmacol 1995; 18: 76-8.
114. Winge K, Skau AM, Stimpel H, Nielsen KK, Werdelin L. Prevalence of bladder dysfunction in Parkinson's disease. Neurourol Urodyn 2006; 25: 116-22.
115. Hobson P, Islam W, Roberts S, Adhiyman V, Meara J. The risk of bladder and autonomic dysfunction in a community cohort of Parkinson's disease patients and normal controls. Parkinsonism Relat Disord 2003; 10: 67-71.
116. Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson's disease. Eur J Neurol 2005; 12: 842-50.
117. Winge K, Werdelin LM, Nielsen KK, Stimpel H. Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourol Urodyn 2004; 23: 689-96.
118. Uchiyama T, Sakakibara R, Hattori T, Yamanishi T, Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon. Mov Disord 2003; 18: 573-8.
119. Papatsoris AG, Deliveliotis C, Singer C, Papapetropoulos S. Erectile dysfunction in Parkinson's disease. Urology 2006; 67: 447-51.
120. Zesiewicz TA, Helal M, Hauser RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Mov Disord 2000; 15: 305-8.
121. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001; 71: 371-4.
122. Raffaele R, Vecchio I, Giammusso B, Morgia G, Brunetto MB, Rampello L. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. Eur Urol 2002; 41: 382-6.
123. Pohanka M, Kanovsky P, Bares M, Pulkrabek J, Rektor I. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial. Parkinsonism Relat Disord 2005; 11: 509-12.
124. Cannas A, Solla P, Floris G,Tacconi P, Loi D, Marcia E, et al. Hypersexual behaviour, frotteurism and delusional jealousy in a young parkinsonian patient during dopaminergic therapy with pergolide: a rare case of iatrogenic paraphilia. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1539-41.
125. Weintraub D, Potenza MN. Impulse control disorders in Parkinson's disease. Curr Neurol Neurosci Rep 2006; 6: 302-6.
126. Swinn L, Schrag A, Viswanathan R, Bloem BR, Lees A, Quinn N. Sweating dysfunction in Parkinson's disease. Mov Disord 2003; 18: 1459-63.
127. Schestatsky P, Valls-Sole J, Ehlers JA, Rieder CR, Gomes I. Hyperhidrosis in Parkinson's disease. Mov Disord 2006; 21: 1744-8.